Treatment With Pirfenidone for COVID-19 Related Severe ARDS

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC), compared to SoC alone, in a population of COVID-19 induced severe ARDS. Patients will be randomized according to 1:1 ratio to one of the trial arms: Pirfenidone (intervention arm) or SoC (control arm).
Epistemonikos ID: 92f748612f705c5aa58a7abc4ca8b49da02427b2
First added on: Dec 05, 2020